BMRN INVESTIGATION ALERT: Bernstein Liebhard is Investigating BioMarin Pharmaceuticals For Violations of the Securities LawsBusiness Wire • 09/28/20
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. – BMRNBusiness Wire • 09/28/20
BMRN LOSSES ALERT: Bernstein Liebhard is Investigating BioMarin Pharmaceuticals For Violations of the Securities LawsBusiness Wire • 09/28/20
Pomerantz Law Firm Announces the Filing of a Class Action against BioMarin Pharmaceuticals, Inc. and Certain Officers - BMRNPRNewsWire • 09/26/20
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Doses First Participant in Global PHEARLESS Phase 1/2 Study of BMN 307 Gene TherapyPRNewsWire • 09/24/20
BioMarin Announces Presentation of Vosoritide Phase 3 Data in Children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual MeetingPRNewsWire • 09/11/20
BioMarin Pharmaceutical (BMRN) Gains As Market Dips: What You Should KnowZacks Investment Research • 09/04/20
BioMarin (BMRN) Down 34.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/03/20
BioMarin Declining Factor Levels Unlikely To Impact Uniqure Or Sangamo Phase 3 Hemophilia TrialsSeeking Alpha • 08/26/20
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?Seeking Alpha • 08/25/20
Nasdaq Falls Off Record Levels; Momenta, BioMarin Head in Opposite DirectionsThe Motley Fool • 08/19/20